Wa Zhang
Overview
Explore the profile of Wa Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stradella A, Johnson M, Goel S, Park H, Lakhani N, Arkenau H, et al.
Cancer Med
. 2024 Jul;
13(13):e7385.
PMID: 38970256
Background: Pamiparib is a potent, selective, poly (ADP-ribose) polymerase 1/2 inhibitor that demonstrates synthetic lethality in cells with breast cancer susceptibility gene mutations or other homologous recombination deficiency. This two-stage...
2.
Xu B, Sun T, Shi Y, Cui J, Yin Y, Ouyang Q, et al.
Breast Cancer Res Treat
. 2022 Dec;
197(3):489-501.
PMID: 36459284
Purpose: To evaluate the efficacy and safety of pamiparib in patients with locally advanced or metastatic human epidermal growth factor receptor 2-negative (HER2-) breast cancer, with deleterious or suspected deleterious...
3.
Xu B, Yin Y, Dong M, Song Y, Li W, Huang X, et al.
Cancer Med
. 2020 Oct;
10(1):109-118.
PMID: 33128299
Background: The recommended phase 2 dose (RP2D) of pamiparib, an investigational PARP1/2 inhibitor, was established as 60 mg twice daily (BID) in a first-in-human (FIH) study (NCT02361723). Methods: Chinese patients...
4.
Zhang W, Klinkebiel D, Barger C, Pandey S, Guda C, Miller A, et al.
Cancers (Basel)
. 2020 Mar;
12(3).
PMID: 32213861
A hallmark of human cancer is global DNA hypomethylation (GDHO), but the mechanisms accounting for this defect and its pathological consequences have not been investigated in human epithelial ovarian cancer...
5.
Sharma A, Albahrani M, Zhang W, Kufel C, James S, Odunsi K, et al.
Epigenetics
. 2019 Feb;
14(2):185-197.
PMID: 30764732
The POTE gene family consists of 14 homologous genes localized to autosomal pericentromeres, and a sub-set of POTEs are cancer-testis antigen (CTA) genes. POTEs are over-expressed in epithelial ovarian cancer...
6.
Barger C, Zhang W, Sharma A, Chee L, James S, Kufel C, et al.
Sci Rep
. 2018 Nov;
8(1):17136.
PMID: 30459449
The POTE family includes 14 genes in three phylogenetic groups. We determined POTE mRNA expression in normal tissues, epithelial ovarian and high-grade serous ovarian cancer (EOC, HGSC), and pan-cancer, and...
7.
Zhang W, Barger C, Eng K, Klinkebiel D, Link P, Omilian A, et al.
Oncotarget
. 2016 Jun;
7(29):45352-45369.
PMID: 27322684
PRAME is a cancer-testis antigen (CTA) and potential immuno-therapeutic target, but has not been well-studied in epithelial ovarian cancer (EOC) or its high grade serous (HGSC) subtype. Compared to normal...
8.
Klinkebiel D, Zhang W, Akers S, Odunsi K, Karpf A
Mol Cancer Res
. 2016 Jun;
14(9):787-94.
PMID: 27259716
Unlabelled: High-grade serous ovarian cancer (HGSC) is the most common and lethal form of epithelial ovarian cancer (EOC). Two distinct tissues have been suggested as the tissue of origin: ovarian...
9.
Barger C, Zhang W, Hillman J, Stablewski A, Higgins M, Vanderhyden B, et al.
Oncotarget
. 2015 Aug;
6(29):27613-27.
PMID: 26243836
The FOXM1 transcription factor network is frequently activated in high-grade serous ovarian cancer (HGSOC), the most common and lethal subtype of epithelial ovarian cancer (EOC). We used primary human EOC...
10.
Zhang W, Barger C, Link P, Mhawech-Fauceglia P, Miller A, Akers S, et al.
Epigenetics
. 2015 Jun;
10(8):736-48.
PMID: 26098711
Epithelial ovarian cancer (EOC) is a highly lethal malignancy due to a lack of early detection approaches coupled with poor outcomes for patients with clinically advanced disease. Cancer-testis (CT) or...